Bardia A et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. San Antonio Breast Cancer Symposium® 2022;Abstract GS3-01.
Bidard F-C et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol 2022;40(28):3246-56. Abstract
Bidard F-C et al. SERENA-6: A phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy. San Antonio Breast Cancer Symposium® 2021;Abstract OT2-11-05.
Ferraro E et al. Accelerating drug development in breast cancer: New frontiers for ER inhibition. Cancer Treat Rev 2022;109:102432. Abstract
Jhaveri K et al. Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study. ESMO 2023;Abstract 383MO.
McDonnell DP et al. Next-generation endocrine therapies for breast cancer. J Clin Oncol 2021;39(12):1383-8. Abstract
Oliveira M et al. Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. San Antonio Breast Cancer Symposium® 2022;Abstract GS3-02.
Turner NC et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): A multicentre, multicohort, phase 2a, platform trial. Lancet Oncol 2020;21(10):1296-308. Abstract
Turner NC et al. ESR1 mutations and overall survival onfulvestrant versus exemestane in advanced hormone receptor-positive breastcancer: A combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res 2020;26(19):5172-7. Abstract
Will M et al. Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nat Rev Cancer 2023;23(10):673-85. Abstract